322 related articles for article (PubMed ID: 16718799)
1. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
[TBL] [Abstract][Full Text] [Related]
4. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation].
Zhao X; Lu S; Wang M; Wu J; Lin D; Guo Q; Lai W; Zeng D; Li C; Liu Y; Sun L; Yan D; Li N
Zhonghua Wai Ke Za Zhi; 2014 Apr; 52(4):245-8. PubMed ID: 24924566
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma.
Campsen J; Zimmerman MA; Trotter JF; Wachs M; Bak T; Mandell S; Kam I
Expert Opin Pharmacother; 2007 Jun; 8(9):1275-82. PubMed ID: 17563262
[TBL] [Abstract][Full Text] [Related]
6. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.
Yanik EL; Chinnakotla S; Gustafson SK; Snyder JJ; Israni AK; Segev DL; Engels EA
Liver Transpl; 2016 May; 22(5):627-34. PubMed ID: 26784951
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus in liver transplant recipients: a large single-center experience.
Vivarelli M; Dazzi A; Cucchetti A; Gasbarrini A; Zanello M; Di Gioia P; Bianchi G; Tamè MR; Gaudio MD; Ravaioli M; Cescon M; Grazi GL; Pinna AD
Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
11. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation.
Campbell MS; Rai J; Kozin E; Bloom RD; Markmann JF; Olthoff KM; Shaked A; Rajender Reddy K
Clin Transplant; 2007; 21(3):377-84. PubMed ID: 17488388
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
[TBL] [Abstract][Full Text] [Related]
15. Indications and management of everolimus after liver transplantation.
Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
17. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
Chang GJ; Mahanty HD; Quan D; Freise CE; Ascher NL; Roberts JP; Stock PG; Hirose R
Liver Transpl; 2000 Nov; 6(6):734-40. PubMed ID: 11084060
[TBL] [Abstract][Full Text] [Related]
18. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
20. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
